The International URBAN Alcohol Research Collaboration on HIV/AIDS (ARCH) Center, funded by the National Institute on Alcohol Abuse and Alcoholism, conducts and disseminates interdisciplinary research on the role of alcohol use among people with HIV on new tuberculosis (TB) acquisition, occurrence of active TB disease after TB preventive therapy, and post-TB lung disease.


LATEST NEWS:

We are happy to announce that the TALC study, led by Dr. Kaku So-Armah, has received supplemental funding to launch the TB HIV Aging in Uganda 50-over-50 (THAU 50/50) study (3P01AA029541-03S1). The THAU study will build on the infrastructure of the TALC study to accomplish the following specific aims:

  • Aim 1: Determine the association between lifetime alcohol exposure and frailty and explore whether a) aging; b) history of TB disease moderates this association among PWH.
  • Aim 2: Determine the association between social vulnerability and a) aging; b) history of TB disease in PWH.
  • Aim 3: Qualitatively elicit health priorities and opportunities for differentiated healthcare delivery among older PWH with prior TB or unhealthy alcohol use.

New Publication: Association of Alcohol Consumption With CD4 Recovery After Antiretroviral Therapy Initiation in St. Petersburg, Russia. (McLaughlin et al., 2023, J Acquir Immune Defic Syndr)

New Publication: Understanding Patients’ Experiences with a Brief Alcohol Reduction Intervention among People Living with HIV in Uganda: A Qualitative Study. (Gichane et al., 2023, Subst Use Misuse)

Check out the latest issue of the quarterly URBAN ARCH Newsletter!

New Publication: Provider-patient experiences and HIV care utilization among people living with HIV who inject drugs in St. Petersburg, Russia. (Raj et al. 2023, Int J Qual Health Care)

New Publication: Rapid access to antiretroviral therapy, receipt of naltrexone, and strengths-based case management versus standard of care for HIV viral load suppression in people with HIV who inject drugs in Russia (LINC-II): an open-label, randomised controlled trial. (Samet et al. 2023, Lancet HIV)

New Publication: Safety and tolerability of isoniazid preventive therapy for tuberculosis for persons with HIV with and without alcohol use. (Hahn et al. 2023, AIDS)

For quarterly updates from URBAN ARCH, click here to join our newsletter list!